Advarra’s Support for Institutions
As clinical research sites face more challenges than perhaps ever before, it’s increasingly important to provide sites with proper support […]
As clinical research sites face more challenges than perhaps ever before, it’s increasingly important to provide sites with proper support […]
For the past two years, the clinical research industry has seen an acceleration in staff shifting to a remote, work
From the largest research centers to the smallest, sites now recognize that a clinical trial management system (CTMS) can be configured to their needs and can bring powerful efficiencies insights, and compliance to their day-to-day operations.
Switching from paper to eSource in clinical trials enhances data accuracy, reduces errors, and boosts organization, offering more efficient study management.
As the COVID-19 pandemic has forced a shift toward remote modalities, mobile health (mHealth) technologies have been on the rise.
Academic research institutions may not face the financial scrutiny of commercial sites, but they still need proper funding to support diverse initiatives.
While electronic source data collection is not new, collecting source data in a variety of settings in a compliant manner is. With this in mind, how does one maintain data quality and integrity while ensuring participant safety and staying compliant?
The landscape of data privacy is certainly dynamic and, at times, imposing. In particular, transferring data across borders can be difficult to navigate.
In this increasingly digital world, we have to remember data is now available in many different medians, including paper. When we think of clinical trials and the critical data
eSource, ePRO, and EDC each play distinct roles in clinical trials, enhancing data consistency, participant experience, and overall study efficiency through technology integration.
The clinical research landscape is likely forever altered by the COVID-19 pandemic, especially regarding trial continuity and the potential for
The Call to Action Data is the most important asset for a pharmaceutical or biotechnology company to produce during clinical